
Opinion|Videos|March 4, 2025
Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals
Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment advances, while highlighting expanding applications in solid tumors, autoimmune disorders, and infectious diseases as promising growth areas for this therapeutic modality.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the most significant recent approvals for bispecific antibodies in oncology?
- What therapeutic areas are seeing growth in bispecific antibody applications?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
3
Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP
4
Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?
5